{
    "clinical_study": {
        "@rank": "100677", 
        "acronym": "ADEPT4", 
        "arm_group": {
            "arm_group_label": "Experimental:  Intervention Group", 
            "arm_group_type": "Experimental", 
            "description": "Experimental:  Intervention Group\n1) Asthma Supervision; 2) Mobile Phone with talking, texting, and data plan; 3) Inhaled Corticosteroid Mobile Phone Application to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated; and 4)  Beta2-adrenergic agonist Mobile Phone Application to monitor real time patterns of use of  beta2-adrenergic agonist medication for asthma."
        }, 
        "brief_summary": {
            "textblock": "This study has two main goals. The first goal is to test whether a mobile phone intervention\n      can increase adherence to daily inhaled steroid medications in African American adolescents\n      prescribed this type of medication by his/her asthma doctor.  The second goal is to use a\n      mobile phone intervention to better understand real life patterns of use of quick-relief\n      (beta2-adrenergic agonist) asthma medication in this population."
        }, 
        "brief_title": "Using Mobile Phones to Improve Adherence to Inhaled Steroids", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  11-16 years of age\n\n          -  self-identify as African American\n\n          -  have persistent asthma\n\n          -  be on a prescription daily inhaled corticosteroid medication for asthma\n\n          -  be on a prescription inhaled beta2-adrenergic agonist medication for   asthma\n\n        Exclusion Criteria:\n\n          -  candidate refusal\n\n          -  the presence of other co-morbidities that could interfere wtih study participation\n\n          -  > 60% adherence to inhaled corticosteroid medication, measured by the electronic dose\n             counter, during the run-in period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "16 Years", 
            "minimum_age": "11 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710059", 
            "org_study_id": "10010402", 
            "secondary_id": "5K23HL092292-04"
        }, 
        "intervention": [
            {
                "arm_group_label": "Experimental:  Intervention Group", 
                "description": "Each participant will be provided with a spacer and a peak flow meter, and instructions on proper technique, by a member of the study team during the baseline period.  They will also meet with study staff at study visits during the active treatment phase to review their adherence to daily inhaled corticosteroids and usage patterns of short acting B2-agonist medication.", 
                "intervention_name": "Asthma Supervision", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": "Experimental:  Intervention Group", 
                "description": "Each participant will receive a mobile phone with talking, texting and a data plan.  They will get to keep the mobile phone at the end of the study, but the talking, texting and data plan will only be active during their participation in the study.", 
                "intervention_name": "Mobile Phone", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": "Experimental:  Intervention Group", 
                "description": "The Inhaled Corticosteroid Mobile Phone Application will be used to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated.", 
                "intervention_name": "Inhaled Corticosteroid Mobile Phone Application", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": "Experimental:  Intervention Group", 
                "description": "The Beta2-adrenergic agonist Mobile Phone Application will be used to track real time patterns of use of beta2-adrenergic agonist medication.", 
                "intervention_name": "Beta2-adrenergic agonist Mobile Phone Application", 
                "intervention_type": "Behavioral"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Adrenergic Agents", 
                "Adrenergic Agonists"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Health Status Disparities", 
            "Minority Health", 
            "Pediatrics", 
            "Behavioral Intervention", 
            "Cellular Phone", 
            "Peer Group"
        ], 
        "lastchanged_date": "February 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60612"
                }, 
                "name": "Rush University Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Refined ADEPT: Human Augmentics for Sustained Wellbeing", 
        "overall_official": {
            "affiliation": "Rush University Medical Center", 
            "last_name": "Giselle S. Mosnaim, MD, MS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Adherence is measured as the mean of daily adherence to prescription inhaled corticosteroid dose over 14 days both at baseline and at week 10 of the active treatment phase.  For the primary outcome, we will compare adherence at week 10 to adherence at baseline.", 
            "measure": "Adherence to inhaled corticosteroids, measured objectively using an electronic dose counter", 
            "safety_issue": "No", 
            "time_frame": "10 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710059"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rush University Medical Center", 
            "investigator_full_name": "Giselle Mosnaim", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "This study will use an electronic dose counter and mobile phone technology to track participants real time use of quick-relief (beta2-adrenergic agonist) medication for asthma during the 10 weeks of active treatment.", 
            "measure": "To understand patterns of use of quick-relief medication for asthma", 
            "safety_issue": "No", 
            "time_frame": "10 weeks"
        }, 
        "source": "Rush University Medical Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "GlaxoSmithKline", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Rush University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}